0.237 -0.005 (-2.07%) | 12-01 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 0.35 | 1-year : | 0.43 |
Resists | First : | 0.3 | Second : | 0.37 |
Pivot price | 0.24 ![]() |
|||
Supports | First : | 0.18 | Second : | 0.15 |
MAs | MA(5) : | 0.24 ![]() |
MA(20) : | 0.25 ![]() |
MA(100) : | 0.45 ![]() |
MA(250) : | 0.82 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 32.9 ![]() |
D(3) : | 26.2 ![]() |
RSI | RSI(14): 43.6 ![]() |
|||
52-week | High : | 1.94 | Low : | 0.18 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GNPX ] has closed above bottom band by 35.0%. Bollinger Bands are 70.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.26 - 0.26 | 0.26 - 0.26 |
Low: | 0.22 - 0.22 | 0.22 - 0.23 |
Close: | 0.23 - 0.24 | 0.24 - 0.24 |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Wed, 29 Nov 2023
Is Genprex Inc (GNPX) Stock a Bad Value? - InvestorsObserver
Thu, 23 Nov 2023
Genprex Granted Orphan Drug Designation in Small Cell Lung Cancer - Yahoo Finance
Fri, 17 Nov 2023
North American Morning Briefing: Stock Futures -2- - Morningstar
Wed, 04 Oct 2023
Genprex to Present Data on the Use of REQORSA® for the ... - PR Newswire
Thu, 21 Sep 2023
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation ... - BioSpace
Mon, 04 Sep 2023
GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 59 (M) |
Shares Float | 59 (M) |
Held by Insiders | 2.3 (%) |
Held by Institutions | 15.8 (%) |
Shares Short | 1,640 (K) |
Shares Short P.Month | 1,650 (K) |
EPS | -0.62 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.2 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -85 % |
Return on Equity (ttm) | -158.1 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.54 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -24 (M) |
Levered Free Cash Flow | -12 (M) |
PE Ratio | -0.39 |
PEG Ratio | 0 |
Price to Book value | 1.12 |
Price to Sales | 0 |
Price to Cash Flow | -0.58 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |